Division of Cardiology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Semin Respir Crit Care Med. 2017 Oct;38(5):585-595. doi: 10.1055/s-0037-1606201. Epub 2017 Oct 15.
Tremendous progress has been made in understanding the genetics of pulmonary arterial hypertension (PAH) since its description in the 1950s as a primary disorder of the pulmonary vasculature. Heterozygous germline mutations in the gene coding bone morphogenetic receptor type 2 (BMPR2) are detectable in the majority of cases of heritable PAH, and in approximately 20% of cases of idiopathic pulmonary arterial hypertension (IPAH). However, recent advances in gene discovery methods have facilitated the discovery of additional genes with mutations among those with and without familial PAH. Heritable PAH is an autosomal dominant disease characterized by reduced penetrance, variable expressivity, and female predominance. Biallelic germline mutations in the gene EIF2AK4 are now associated with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Growing genetic knowledge enhances our capacity to pursue and provide genetic counseling, although the issue remains complex given that the majority of carriers of PAH-related mutations will never be diagnosed with the disease.
自 20 世纪 50 年代首次描述肺动脉高压(PAH)为肺血管原发性疾病以来,人们对其遗传学的理解取得了巨大进展。在大多数遗传性 PAH 病例和大约 20%的特发性肺动脉高压(IPAH)病例中,可检测到编码骨形态发生受体型 2(BMPR2)的基因的杂合胚系突变。然而,基因发现方法的最新进展促进了在有和没有家族性 PAH 的患者中发现具有突变的其他基因。遗传性 PAH 是一种常染色体显性疾病,其特征为外显率低、表现度可变和女性为主。EIF2AK4 基因的双等位基因胚系突变现在与肺静脉闭塞病和肺毛细血管血管瘤病相关。遗传知识的不断增加增强了我们进行遗传咨询的能力,尽管鉴于大多数 PAH 相关突变携带者永远不会被诊断出患有该疾病,这个问题仍然很复杂。